Work Here?
Nautilus Biotechnology
Work Here?
Proteomics platform for drug development insights
Nautilus Biotechnology
Work Here?
Proteomics platform for drug development insights
About Nautilus Biotechnology
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Total Funding
$294.9M
Headquarters
San Carlos, California
Founded
2016
Overview
Nautilus Biotechnology focuses on the study of proteins, known as proteomics, to enhance drug development. The company has created a platform that helps researchers gain detailed insights into how drug targets function in both health and disease. This platform allows users to identify and prioritize drug targets that are more likely to succeed in clinical settings, which helps to minimize the time and costs typically associated with drug discovery. Nautilus Biotechnology primarily serves pharmaceutical companies, research institutions, and biotech firms, providing them with tools to improve their research and clinical outcomes. Unlike many competitors, Nautilus emphasizes the importance of understanding the proteome to drive advancements in biology and medicine. The ultimate goal of Nautilus is to contribute positively to global health by facilitating breakthroughs in drug development.
Simplify's Take
What believers are saying
- Nautilus' platform accelerates drug development by providing deep insights into drug targets.
- The collaboration with SkyWater enhances precision medicine through advanced protein analysis.
- Recent patent grants strengthen Nautilus' intellectual property and competitive position.
What critics are saying
- Potential delays in platform launch could impact revenue and investor confidence.
- SPAC-related share price drops may affect market valuation and capital raising.
- Dependency on SkyWater for bio chip production poses supply chain risks.
What makes Nautilus Biotechnology unique
- Nautilus Biotechnology pioneers a single-molecule protein analysis platform for proteomics.
- The company integrates diverse expertise, from protein chemists to software engineers.
- Nautilus aims to democratize proteomics, transforming drug development and medical diagnostics.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$294.9M
Above
Industry Average
Funded Over
4 Rounds
Andreessen HorowitzGrowth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%SEATTLE, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the TD Cowen 45th Annual Healthcare Conference.Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 3, 2025, at 1:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine
Nautilus Biotechnology (NASDAQ: NAUT) announced that its co-founder and Chief Scientist, Parag Mallick, Ph.D., has been awarded the 2024 Distinguished Investigator Award by the Academy for Radiology and Biomedical Imaging Research.
SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) - Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer.
The collaboration between SkyWater and Nautilus is set to contribute to the advancement of precision medicine by enhancing protein analysis through semiconductor manufacturing.
NEW YORK - Nautilus Biotechnology may not hit its previously stated goal of commercially launching its proteomics platform by the middle of the year, GenomeWeb has learned.
There are no jobs for Nautilus Biotechnology right now.
Find jobs on Simplify and start your career today
About Nautilus Biotechnology
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Total Funding
$294.9M
Headquarters
San Carlos, California
Founded
2016
There are no jobs for Nautilus Biotechnology right now.
Find jobs on Simplify and start your career today